Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Other Accumulated Expenses (2022 - 2025)

Vivos Therapeutics (VVOS) has disclosed Other Accumulated Expenses for 4 consecutive years, with $987000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 395.98% to $987000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $987000.0, a 395.98% increase, with the full-year FY2024 number at $273000.0, up 37.88% from a year prior.
  • Other Accumulated Expenses was $987000.0 for Q3 2025 at Vivos Therapeutics, down from $1.0 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.0 million in Q2 2025 to a low of $127000.0 in Q1 2023.
  • A 4-year average of $363571.4 and a median of $248500.0 in 2024 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: tumbled 55.68% in 2023, then surged 572.19% in 2025.
  • Vivos Therapeutics' Other Accumulated Expenses stood at $145000.0 in 2022, then soared by 36.55% to $198000.0 in 2023, then skyrocketed by 37.88% to $273000.0 in 2024, then skyrocketed by 261.54% to $987000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Other Accumulated Expenses are $987000.0 (Q3 2025), $1.0 million (Q2 2025), and $672000.0 (Q1 2025).